Literature DB >> 19381688

Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China.

Jia Fan1, Guang-Shun Yang, Zhi-Ren Fu, Zhi-Hai Peng, Qiang Xia, Chen-Hong Peng, Jian-Ming Qian, Jian Zhou, Yang Xu, Shuang-Jian Qiu, Lin Zhong, Guang-Wen Zhou, Jian-Jun Zhang.   

Abstract

PURPOSE: To evaluate current selection criteria for patients undergoing liver transplantation (LT) in response to hepatocellular carcinoma (HCC), and to analyze the prognostic factors for successful transplantation.
METHODS: We evaluated the outcome of 1,078 consecutive patients with HCC from the Shanghai Multi-Center Collaborative LT Group who underwent LT over a 6-year period. Clinicopathologic data for these patients were evaluated. The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. Multivariate study with Cox's proportional hazard model was used to evaluate the prognosis-relative aspects.
RESULTS: We determined that expansion of Milan criteria to include: a solitary lesion < or = 9 cm in diameter, no more than three lesions with the largest < or = 5 cm, a total tumor diameter < or = 9 cm without macrovascular invasion, lymph node invasion and extrahepatic metastasis (referred to as the "Shanghai criteria"), resulted in overall survival (OS) and disease-free survival (DFS) rates that were similar to the Milan criteria. Multivariate analysis using the Cox proportional hazards regression model showed that the Child-Pugh-Turcotte classification (P = 0.010, 0.000), tumor differentiation (P = 0.001, 0.000), tumor size (P = 0.000, 0.000) and number (P = 0.014, 0.016), macrovascular invasion (P = 0.022, 0.000) and alpha-fetoprotein (AFP) levels (P = 0.031, 0.003) were independent predictors of OS and DFS, while post-LT chemotherapy (OS, P = 0.000) and tumor encapsulation (DFS, P = 0.038) were independent predictors of OS or DFS.
CONCLUSION: Shanghai criteria expanded the current criteria while maintaining similar survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381688     DOI: 10.1007/s00432-009-0584-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

2.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

4.  Results of liver transplantation for hepatocellular cancer.

Authors:  Krzysztof Zieniewicz; Waldemar Patkowski; Paweł Nyckowski; Abdulsalam Alsharabi; Bogdan Michałowicz; Jacek Pawlak; Rafał Paluszkiewicz; Tadeusz Wróblewski; Bogusław Najnigier; Piotr Smoter; Piotr Hevelke; Anna Skwarek; Piotr Remiszewski; Marcin Kotulski; Michał Skalski; Leszek Paczek; Marek Krawczyk
Journal:  Ann Transplant       Date:  2007       Impact factor: 1.530

5.  Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors.

Authors:  B Pérez-Saborido; S Jiménez de los Galanes; J C Menéu-Díaz; C Jiménez Romero; A Moreno Elola-Olaso; Y Fundora Suárez; V Barra Valencia; E Moreno-González
Journal:  Transplant Proc       Date:  2007-09       Impact factor: 1.066

6.  Outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma.

Authors:  M Rossi; M Merli; Q Lai; F Gentili; G Mennini; A Bussotti; F Pugliese; F Della Pietra; L Poli; G Novelli; M Giusto; S Ginanni Corradini; M Iappelli; A Onetti Muda; U Di Tondo; F Gossetti; A F Attili; P B Berloco
Journal:  Transplant Proc       Date:  2007 Jul-Aug       Impact factor: 1.066

7.  Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation.

Authors:  Shigeru Marubashi; Keizo Dono; Hiroaki Nagano; Yukari Sugita; Tadafumi Asaoka; Naoki Hama; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Morito Monden
Journal:  Transpl Int       Date:  2007-04-08       Impact factor: 3.782

Review 8.  Liver transplantation for hepatocellular carcinoma in Asia.

Authors:  Vanessa de Villa; Chung Mau Lo
Journal:  Oncologist       Date:  2007-11

9.  A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.

Authors:  J Shi; L Zhu; S Liu; W-F Xie
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

Review 10.  Liver transplantation for hepatocellular carcinoma.

Authors:  Vincenzo Mazzaferro; Yun Shin Chun; Ronnie T P Poon; Myron E Schwartz; Francis Y Yao; J Wallis Marsh; Sherrie Bhoori; Sung-Gyu Lee
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

View more
  40 in total

Review 1.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

2.  "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China.

Authors:  Jian-Yong Lei; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

3.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

4.  Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.

Authors:  Ping Wan; Jian-Jun Zhang; Qi-Gen Li; Ning Xu; Ming Zhang; Xiao-Song Chen; Long-Zhi Han; Qiang Xia
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 5.  Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China.

Authors:  Shukui Qin; Xinlei Gong
Journal:  Hepat Oncol       Date:  2015-11-30

6.  Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.

Authors:  Fei Teng; Gui-Hua Wang; Yi-Feng Tao; Wen-Yuan Guo; Zheng-Xin Wang; Guo-Shan Ding; Xiao-Min Shi; Zhi-Ren Fu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 7.  Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review.

Authors:  Dong-Wei Xu; Ping Wan; Qiang Xia
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

8.  Prominent effect of platelet on improvement of liver cirrhosis.

Authors:  Hui Xu; Xiao-Meng Jiang; Ying Wu; Yu-Mei Li; Yun-Wen Zheng; Nobuhiro Ohkohchi
Journal:  AME Case Rep       Date:  2020-04-30

9.  Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma.

Authors:  Xiangting Qiu; Xinhua Wang; Yucui Song; Lingling Chen
Journal:  Dig Dis Sci       Date:  2016-10-03       Impact factor: 3.199

10.  Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Authors:  Yuanxi Jia; Li Li; Fuqiang Cui; Dongliang Zhang; Guomin Zhang; Fuzhen Wang; Xiaohong Gong; Hui Zheng; Zhenhua Wu; Ning Miao; Xiaojin Sun; Li Zhang; Jingjing Lv; Feng Yang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.